PCMA Business Forum 2024

Our experts will be available to discuss these priority topics

Inflation Reduction Act (IRA) Implementation: As the IRA continues to be implemented, manufacturers should understand the changes they can expect in 2024 including the Medicare Prescription Payment Plan Guidance. Disruption and adjustments in product flow will require cross-functional awareness, and a likely pivot in drug launch and access strategy and contracting with channel, pharmacy, provider, and health plans.  

2026 Part D Strategy and Bid Modeling: Manufacturers can expect Part D volume and revenue changes and should prepare for new plan approaches to formulary and benefit design. As 2025 contracting comes to an end, manufacturers should be prepared for 2026 contracting strategy. Avalere can be a thought partner to manufacturers developing their strategy for engaging Part D plans using qualitative and quantitative approaches to demonstrate value.  

Patient Affordability and Access: The dynamic access landscape brought forth by market pressures (such as copay adjustment programs and alternative funding programs) as well as state and federal policies will create new challenges for patient access and affordability efforts from manufacturers, foundations, and patient advocacy organizations. Avalere provides expert guidance on navigating payer access challenges and policy changes such as Prescription Drug Affordability Review Boards (PDABs), Upper Payment Limits, and PBM regulation, including and modeling potential impacts and advising on strategies to advance pricing, coverage and access objectives.